Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France
The international phase IIIb study, ATHENA assessed the combination of bevacizumab/taxane-based chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (mBC) in real-life setting. Among the 365 patients included in France, median overall survival (OS) is 28.4 months (CI95% 24.8-33.0), with a median time from treatment start to end of study of 36,5 months (25,1-45,4). Exploratory analyses in three sub-groups show that the median OS in long responder patients (not progressing for at least one year; n = 116) is not reached. In responder patients (n = 308), median OS is 33.0 months (CI95% 28.6-37.4) and 12.4 months (CI95% 11.2-17.4) in non-responders (n = 41). In patients with mBC expressing hormone receptors (HR+), treated with first-line hormone therapy before inclusion (n = 87) median OS in is 23.2 months (CI95% 19.6-28.6), and 35.3 months (CI95% 32.2-not reached); P = 0.004 in patients treated first with chemotherapy + bevacizumab (n = 179). The safety analysis in the various sub-groups of grade 3-5 adverse events of particular interest to bevacizumab of this study was comparable to the safety data of randomized phase III studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
|---|---|
| Enthalten in: |
Bulletin du cancer - 101(2014), 9 vom: 07. Sept., Seite 780-8 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Bévacizumab et taxanes dans le traitement de première ligne du cancer du sein métastatique : survie globale et analyse de sous-groupes de l'étude ATHENA France |
|---|
| Beteiligte Personen: |
Pierga, Jean-Yves [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.03.2015 Date Revised 25.11.2016 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1684/bdc.2014.2019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM24259655X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM24259655X | ||
| 003 | DE-627 | ||
| 005 | 20231224130734.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1684/bdc.2014.2019 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0808.xml |
| 035 | |a (DE-627)NLM24259655X | ||
| 035 | |a (NLM)25295737 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Pierga, Jean-Yves |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer |b overall survival and subgroup analyses of the ATHENA study in France |
| 246 | 3 | 3 | |a Bévacizumab et taxanes dans le traitement de première ligne du cancer du sein métastatique : survie globale et analyse de sous-groupes de l'étude ATHENA France |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.03.2015 | ||
| 500 | |a Date Revised 25.11.2016 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The international phase IIIb study, ATHENA assessed the combination of bevacizumab/taxane-based chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (mBC) in real-life setting. Among the 365 patients included in France, median overall survival (OS) is 28.4 months (CI95% 24.8-33.0), with a median time from treatment start to end of study of 36,5 months (25,1-45,4). Exploratory analyses in three sub-groups show that the median OS in long responder patients (not progressing for at least one year; n = 116) is not reached. In responder patients (n = 308), median OS is 33.0 months (CI95% 28.6-37.4) and 12.4 months (CI95% 11.2-17.4) in non-responders (n = 41). In patients with mBC expressing hormone receptors (HR+), treated with first-line hormone therapy before inclusion (n = 87) median OS in is 23.2 months (CI95% 19.6-28.6), and 35.3 months (CI95% 32.2-not reached); P = 0.004 in patients treated first with chemotherapy + bevacizumab (n = 179). The safety analysis in the various sub-groups of grade 3-5 adverse events of particular interest to bevacizumab of this study was comparable to the safety data of randomized phase III studies | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a bevacizumab | |
| 650 | 4 | |a first-line | |
| 650 | 4 | |a metastatic breast cancer | |
| 650 | 4 | |a sub-groups | |
| 650 | 4 | |a survival | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Bridged-Ring Compounds |2 NLM | |
| 650 | 7 | |a Taxoids |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 650 | 7 | |a taxane |2 NLM | |
| 650 | 7 | |a 1605-68-1 |2 NLM | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Delva, Rémy |e verfasserin |4 aut | |
| 700 | 1 | |a Pivot, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Espié, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Dalenc, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Serin, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Veyret, Corinne |e verfasserin |4 aut | |
| 700 | 1 | |a Lortholary, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Gligorov, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Joly, Katelle |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandez, Juana |e verfasserin |4 aut | |
| 700 | 1 | |a Hardy-Bessard, Anne-Claire |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin du cancer |d 1966 |g 101(2014), 9 vom: 07. Sept., Seite 780-8 |w (DE-627)NLM000155853 |x 1769-6917 |7 nnns |
| 773 | 1 | 8 | |g volume:101 |g year:2014 |g number:9 |g day:07 |g month:09 |g pages:780-8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1684/bdc.2014.2019 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 101 |j 2014 |e 9 |b 07 |c 09 |h 780-8 | ||